Eli Lilly has quietly provided its investigational weight-loss drug retatrutide to just one person under a compassionate use program. The disclosure was made in a STAT News report that highlighted the narrow scope of access to the so-called triple-G therapy.
Retatrutide, which targets three gut hormone receptors, is among a new class of highly anticipated obesity treatments still in clinical trials. The drug's developer has not publicly detailed why this specific patient qualified or how the decision was made.
Compassionate use programs allow patients with serious conditions to access unapproved medicines when no alternatives exist. Yet the extreme limitation to a single recipient has drawn scrutiny, as thousands of patients with severe obesity or related conditions might theoretically seek such access.
The move underscores the tension between drugmakers' desire to control investigational therapies and the unmet need for effective obesity treatments. It remains unclear whether Lilly plans to expand the program or if this was a one-off exception.
Critics argue the lack of transparency around eligibility could undermine trust in these access pathways. The company has not commented beyond confirming the single-use case.